Korean Pharma Receives MFDS Approval for Antidepressant 'Pharma Maltazapine Tablets'..."Expecting Synergy with Other Antidepressants"

Korea Pharma announced on the 23rd that it has received generic approval from the Ministry of Food and Drug Safety for the antidepressant 'Pharma Mirtazapine Tablets.' The approved dosages are 7.5mg, 15mg, and 30mg, totaling three types.

Pharma Mirtazapine Tablets (active ingredient: Mirtazapine) belong to the noradrenaline and specific serotonergic antidepressant (NaSSA) class. It is effective for patients with depression accompanied by sleep disorders and reduces side effects such as sexual dysfunction, nausea, and vomiting compared to selective serotonin reuptake inhibitor (SSRI) antidepressants.

Earlier, Korea Pharma strengthened its antidepressant product lineup by introducing 'Trittico Tablets,' a generic equivalent of Trazodone, in July. In August, it launched 'Pharma Desvenlafaxine Extended-Release Tablets,' the first domestic generic equivalent of Pristiq (active ingredient: Desvenlafaxine) in the market.

A Korea Pharma representative stated, “With the approval of the antidepressant containing mirtazapine, which is prescribed as a first-line treatment for depression in clinical settings, we expect to expand our market dominance. Along with our competitively strong existing antidepressant products, this will help improve profitability.”

Meanwhile, the company also received generic approval on the 9th for the migraine treatment 'Naramic Tablets.' This drug is an orally disintegrating formulation that improves medication convenience and is a second-generation triptan class oral migraine specialist treatment that selectively acts on serotonin receptors in the brain. It can be prescribed for the rapid relief of migraines with or without aura.

This content was produced with the assistance of AI translation services.